TAK-875, a selective FFAR1 agonist, has been found to increase insulin secretion and improve glucose tolerance without causing hypoglycemia and other serious side effects in patients with type II diabetes for the first time, making it a potential new treatment for type II diabetes, as reported by Leifke et al. and Araki et al. [97,98]. Here, INS is linked to type 2 diabetes mellitus.